Ostenil (Alendronate Sodium Trihydrate)

Alendronate binds to hydroxy‑apatite at active bone remodeling sites and is taken up by osteoclasts. It inhibits the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway, which impairs osteoclast function and reduces bone resorption, leading to a net gain in bone mass.

The specific dose of Ostenil is determined by the prescribing clinician based on the patient’s condition, renal function, and other clinical factors. Healthcare professionals set the appropriate regimen and dosing schedule according to approved prescribing information.

Alendronate is generally contraindicated in pregnancy because it can cross the placenta and affect fetal bone development. It is also not recommended while breastfeeding, as it may be excreted in milk. Women who are pregnant, planning pregnancy, or nursing should discuss alternative therapies with their healthcare provider.

To order Ostenil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ostenil (alendronate) is a first‑line oral bisphosphonate, offering a convenient once‑weekly or daily dosing option. Compared with intravenous bisphosphonates such as zoledronic acid, alendronate has a lower risk of acute infusion reactions but requires strict administration instructions to minimise gastrointestinal irritation.

Store Ostenil tablets at ambient temperature, below 25 °C, in the original container. Protect the product from moisture and direct sunlight to maintain stability throughout its shelf life.

Ostenil tablets are taken orally with a full glass of plain water, first thing in the morning, at least 30 minutes before any food, drink or other medication. Patients should remain upright for at least 30 minutes after ingestion to reduce the risk of esophageal irritation.

Serious adverse events linked to alendronate include esophageal ulceration or perforation, atypical femoral fractures, osteonecrosis of the jaw, severe acute phase reactions, and significant hypocalcaemia. Patients should be monitored for these conditions and advised to report any related symptoms promptly.

Ostenil is contraindicated in individuals with known hypersensitivity to alendronate or other bisphosphonates, those with esophageal abnormalities that delay emptying, and patients with severe renal impairment (creatinine clearance <30 mL/min). It should also be avoided in pregnant or nursing women.